UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of October 2022 (Report No. 4)

 

Commission file number: 001-39957

 

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

 

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____

 

 

 

 

 

 

CONTENTS

 

This Report of Foreign Private Issuer on Form 6-K consists of (i) NLS Pharmaceutics Ltd.’s, or the Registrant’s, Condensed Financial Statements (unaudited) as of June 30, 2022, which is attached hereto as Exhibit 99.1; and (iii) the Registrant’s Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2022, which is attached hereto as Exhibit 99.2.

 

This report on Form 6-K is incorporated by reference into the Registrant’s Registration Statement on Form F-3 (File No. 333-262489), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

EXHIBIT INDEX

 

Exhibit No.   Document Description
99.1   Condensed Financial Statements (Unaudited) of NLS Pharmaceutics as of and for the six months ended June 30, 2022.
99.2   Management’s Discussion and Analysis of Financial Condition and Results of Operations.
EX-101.INS   Inline XBRL Taxonomy Instance Document
EX-101.SCH   Inline XBRL Taxonomy Extension Schema Document
EX-101.CAL   Inline XBRL Taxonomy Calculation Linkbase Document
EX-101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
EX-101.LAB   Inline XBRL Taxonomy Label Linkbase Document
EX-101.PRE   Inline XBRL Taxonomy Presentation Linkbase Document
EX-104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  NLS Pharmaceutics Ltd.
     
Date: October 11, 2022 By: /s/ Alexander Zwyer
    Name:  Alexander Zwyer
    Title: Chief Executive Officer

 

2

 

NLS Pharmaceutics Ltd. false --12-31 Q2 2022 2022-06-30 0001783036 0001783036 2022-01-01 2022-06-30 0001783036 2022-06-30 0001783036 2021-12-31 0001783036 2022-01-02 2022-06-30 0001783036 2021-01-02 2021-06-30 0001783036 us-gaap:CommonStockMember 2021-12-31 0001783036 us-gaap:TreasuryStockMember 2021-12-31 0001783036 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001783036 us-gaap:RetainedEarningsMember 2021-12-31 0001783036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001783036 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001783036 us-gaap:TreasuryStockMember 2022-01-01 2022-06-30 0001783036 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0001783036 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001783036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-06-30 0001783036 us-gaap:CommonStockMember 2022-06-30 0001783036 us-gaap:TreasuryStockMember 2022-06-30 0001783036 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001783036 us-gaap:RetainedEarningsMember 2022-06-30 0001783036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001783036 us-gaap:CommonStockMember 2020-12-31 0001783036 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001783036 us-gaap:RetainedEarningsMember 2020-12-31 0001783036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001783036 2020-12-31 0001783036 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001783036 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001783036 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001783036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-06-30 0001783036 2021-01-01 2021-06-30 0001783036 us-gaap:CommonStockMember 2021-06-30 0001783036 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001783036 us-gaap:RetainedEarningsMember 2021-06-30 0001783036 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001783036 2021-06-30 0001783036 2021-01-01 0001783036 2021-02-02 2021-02-02 0001783036 2021-02-02 0001783036 nlsp:BackgroundMember 2021-02-02 0001783036 nlsp:GoingConcernMember 2022-01-01 2022-06-30 0001783036 us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-06-30 0001783036 us-gaap:SoftwareDevelopmentMember 2022-01-01 2022-06-30 0001783036 2021-01-01 2021-12-31 0001783036 us-gaap:FurnitureAndFixturesMember 2022-06-30 0001783036 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001783036 us-gaap:SoftwareDevelopmentMember 2022-06-30 0001783036 us-gaap:SoftwareDevelopmentMember 2021-12-31 0001783036 2022-01-31 0001783036 2021-03-01 2021-03-10 0001783036 2022-04-25 0001783036 2022-03-01 2022-03-05 0001783036 2022-03-31 0001783036 2022-03-01 2022-03-31 0001783036 2022-04-01 2022-04-13 0001783036 us-gaap:WarrantMember 2022-04-25 0001783036 us-gaap:WarrantMember 2022-04-01 2022-04-25 0001783036 2021-12-01 2021-12-14 0001783036 2019-10-31 0001783036 2019-10-01 2019-10-31 0001783036 nlsp:ConsultingAgreementMember 2022-01-01 2022-06-30 0001783036 nlsp:ConsultingAgreementMember 2021-01-01 2021-06-30 0001783036 nlsp:CHGBioVentureSAMember 2020-10-31 0001783036 nlsp:CHGBioVentureSAMember 2020-10-01 2020-10-31 0001783036 nlsp:CHGBioVentureSAMember 2022-01-01 2022-06-30 0001783036 nlsp:CHGBioVentureSAMember 2021-01-01 2021-06-30 0001783036 nlsp:MrRoyMember 2021-03-01 2021-03-31 0001783036 nlsp:MrRoyMember 2022-01-01 2022-06-30 0001783036 nlsp:MrRoyMember 2021-01-01 2021-06-30 0001783036 nlsp:MrKonofalMember 2021-02-01 2021-02-28 0001783036 nlsp:MrKonofalMember 2022-01-01 2022-06-30 0001783036 nlsp:MrKonofalMember 2021-01-01 2021-06-30 0001783036 nlsp:MrCamozziMember 2021-03-01 2021-03-31 0001783036 nlsp:MrCamozziMember 2022-01-01 2022-06-30 0001783036 nlsp:MrCamozziMember 2021-01-01 2021-06-30 0001783036 nlsp:MrHellmannMember 2022-06-30 0001783036 nlsp:MrHellmannMember 2022-01-01 2022-06-30 0001783036 2022-07-21 0001783036 2022-08-19 2022-08-19 0001783036 2022-08-19 0001783036 2022-09-30 iso4217:USD iso4217:CHF xbrli:shares iso4217:USD xbrli:shares xbrli:shares xbrli:pure iso4217:CHF